This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.
The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... The validation of our EU marketing application is an important step towards addressing the
MHRA has authorised drug for HER2-positive advanced breast cancer. Seagen’s oral HER2 drug Tukysa has been granted authorisation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ... added. Last week, the European Commission also
Despite failing in NSCLC, bintrafusp alfa will continue to be evaluated in a number of additional clinical trials across a range of cancer types. ... Merck. The German pharma company also recently initiated monotherapy studies in triple-negative breast
The ADC is currently in phase 2 clinical trials for breast cancer and other solid tumours, and will go on to be developed as a monotherapy and in combination with Merck ... Tukysa was approved by the US Food and Drug Administration (FDA) in April this
Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... TNBC is an aggressive and hard-to-treat
It will become available for patients across England who have hormone receptor-positive, HER2-negative, advanced breast cancer who have already had endocrine therapy. ... Ibrance is already available via the CDF as a second-line breast cancer treatment
More from news
Approximately 1 fully matching, plus 158 partially matching documents found.
advanced or refractory HER2-positive metastatic breast cancer, DS-8201 was recently approved by the FDA with the brand name Enhertu for the treatment of adult patients with unresectable or metastatic ... HER2 positive breast cancer who have received two
The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
She told me I had advanced breast cancer and urged me to drive down to the local emergency room immediately to get additional tests and start chemotherapy that weekend. ... I was diagnosed with inflammatory breast cancer (IBC) with axillary lymph node
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy
The Fight Forward campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories for the agency.
The “Fight Forward” campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...